Logo image of NUMI.CA

NUMINUS WELLNESS INC (NUMI.CA) Stock Fundamental Analysis

TSX:NUMI - Toronto Stock Exchange - CA67054W1032 - Common Stock - Currency: CAD

0.05  +0.02 (+42.86%)

Fundamental Rating

3

Taking everything into account, NUMI scores 3 out of 10 in our fundamental rating. NUMI was compared to 33 industry peers in the Pharmaceuticals industry. NUMI may be in some trouble as it scores bad on both profitability and health. NUMI shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUMI has reported negative net income.
In the past year NUMI has reported a negative cash flow from operations.
NUMI had negative earnings in each of the past 5 years.
NUMI had a negative operating cash flow in each of the past 5 years.
NUMI.CA Yearly Net Income VS EBIT VS OCF VS FCFNUMI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -213.24%, NUMI is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
With a Return On Equity value of -644.74%, NUMI is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -213.24%
ROE -644.74%
ROIC N/A
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUMI.CA Yearly ROA, ROE, ROICNUMI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

With a Gross Margin value of 32.02%, NUMI perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
NUMI's Gross Margin has improved in the last couple of years.
NUMI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
NUMI.CA Yearly Profit, Operating, Gross MarginsNUMI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

NUMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NUMI has been increased compared to 1 year ago.
NUMI has more shares outstanding than it did 5 years ago.
NUMI has a worse debt/assets ratio than last year.
NUMI.CA Yearly Shares OutstandingNUMI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
NUMI.CA Yearly Total Debt VS Total AssetsNUMI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NUMI has an Altman-Z score of -13.73. This is a bad value and indicates that NUMI is not financially healthy and even has some risk of bankruptcy.
NUMI has a worse Altman-Z score (-13.73) than 81.82% of its industry peers.
NUMI has a Debt/Equity ratio of 0.95. This is a neutral value indicating NUMI is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.95, NUMI is doing worse than 78.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Altman-Z -13.73
ROIC/WACCN/A
WACC8.99%
NUMI.CA Yearly LT Debt VS Equity VS FCFNUMI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.40 indicates that NUMI should not have too much problems paying its short term obligations.
NUMI's Current ratio of 1.40 is in line compared to the rest of the industry. NUMI outperforms 51.52% of its industry peers.
A Quick Ratio of 1.40 indicates that NUMI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.40, NUMI is in the better half of the industry, outperforming 60.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
NUMI.CA Yearly Current Assets VS Current LiabilitesNUMI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

NUMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.67%, which is quite impressive.
The Revenue has grown by 22.69% in the past year. This is a very strong growth!
NUMI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 197.54% yearly.
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%

3.2 Future

NUMI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.53% yearly.
NUMI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.63% yearly.
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NUMI.CA Yearly Revenue VS EstimatesNUMI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
NUMI.CA Yearly EPS VS EstimatesNUMI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUMI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUMI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUMI.CA Price Earnings VS Forward Price EarningsNUMI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUMI.CA Per share dataNUMI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1

4.3 Compensation for Growth

NUMI's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.44%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

NUMI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUMINUS WELLNESS INC

TSX:NUMI (1/29/2025, 7:00:00 PM)

0.05

+0.02 (+42.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-13 2025-01-13
Earnings (Next)N/A N/A
Inst Owners2.66%
Inst Owner ChangeN/A
Ins Owners3.55%
Ins Owner ChangeN/A
Market Cap16.12M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.62
P/FCF N/A
P/OCF N/A
P/B 3.48
P/tB 3.48
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.08
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -213.24%
ROE -644.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.02%
FCFM N/A
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
F-Score2
Asset Turnover1.86
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.51%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -13.73
F-Score2
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)61.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)21.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%
EBIT growth 1Y24.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.26%
OCF growth 3YN/A
OCF growth 5YN/A